1 Detection of carbapenem resistance genes in Campylobacter coli and Campylobacter jejuni 2 isolated from chickens, and diarrheic children aged less than five years in Kampala city, 3 Uganda. Walter Okello^{1,2}, Ann Nanteza¹, Felix Opiyo¹, Justin Okello¹, Lesley Rose Ninsiima¹, Peter 4 Marin¹, David Onafruo¹, Patrick Pithua³, Clovice Kankya¹, Terence Odoch¹ 5 6 7 ¹Department of Biosecurity Ecosystems and Veterinary Public Health, College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, P.O. Box 7062, 8 9 Kampala, Uganda 10 ²International Institute of Tropical Agriculture, P.O. Box 7878, Kampala, Uganda ³Department of Population Health Sciences, Virginia-Maryland College of Veterinary Medicine, 11 12 Virginia Polytechnic Institute and State University, Blacksburg, 24061, United States 13 *Correspondence, walteriqueokello@gmail.com/ W.Okello@cgiar.org, +256 783923827 14 15 **Keywords** 16 Carbapenem resistance genes, Campylobacter coli, Campylobacter jejuni, Chickens, Diarrheic 17 children aged less than five years. 18

19 Abstract

Campylobacter species are recognized as one of the significant causative agents of global
foodborne illnesses and potential reservoirs for dissemination of antimicrobial resistance due to
their zoonotic nature. Unlike other bacteria such as *Klebsiella pneumoniae*, *E. coli*, *Enterobacter*,
etc., *Campylobacter* has shown limited or absent resistance to Carbapenems, critically important
"last resort" antibiotics. This distinct resistance profile prompted this investigation into the
prevalence of Carbapenem resistance genes in *Campylobacter* species, specifically *Campylobacter coli* (*C. coli*) and *Campylobacter jejuni* (*C. jejuni*).

Analyses were conducted on 292 archived *C. coli* and *C. jejuni* isolates obtained from chickens and diarrheic children under five years of age in Kampala city, Uganda. The primary objectives included assessment of phenotypic susceptibility of the isolates to Meropenem and Imipenem using the Kirby Bauer disk diffusion method, as well as determination of the occurrence of four selected Carbapenem resistance genes (blaVIM, blaNDM-1, blaIMP, and blaOXA-48) using

32 multiplex polymerase chain reaction (PCR).

33 Interestingly, despite the observed phenotypic susceptibility to Meropenem and Imipenem in all 34 the Campylobacter isolates, 29.8% harbored at least one of the four selected Carbapenem 35 resistance genes, including blaVIM, blaNDM-1, blaIMP, and blaOXA-48. The prevalence of the resistance genes was 55(28.1%) in chickens and 15(38.5%) in children. Notably, blaVIM was the 36 predominant gene, detected in 57.1% of the isolates, followed by blaNDM-1 (11.4%), blaIMP 37 (8.6%), and blaOXA-48 (5.7%). Coexistence of multiple resistance genes was also observed, with 38 blaVIM and blaIMP present in 10.0% of the isolates, and blaVIM and blaNDM-1 in 5.7%. One 39 40 isolate displayed simultaneous presence of blaNDM-1, blaVIM, and blaIMP. This study uncovered a previously unexplored realm in *Campvlobacter* research, identifying 41 42 Carbapenem resistance genes in *Campylobacter* in Uganda. The identification of these resistance

43 genes, despite the apparent phenotypic susceptibility to Carbapenems, signifies the presence of a

44 substantial reservoir of carbapenem resistance genes in *Campylobacter*.

45

46

47 Introduction

Antimicrobial resistance (AMR) is an increasing global threat to public health, posing a significant 48 49 risk to vulnerable populations, including neonates, critically ill patients, and those with weakened 50 immune systems [1]. The World Health Organization [2] has identified AMR as a global health 51 security concern, emphasizing the need for action across government sectors and society as a 52 whole. In the United States alone, the Centers for Disease Control (CDC) estimated that AMR-53 related direct healthcare costs could reach up to \$20 billion annually, with additional costs of up to \$35 billion per year in terms of lost productivity [3]. Moreover, a report released by the Uganda 54 55 National Academy of Sciences in 2015 highlighted the worsening trends of resistance and the diminishing effectiveness of commonly used antibiotics in Uganda [4]. 56

In response to the rising AMR threat, Uganda has taken significant steps to combat the spread of antibiotic resistance. Notably, the country has developed a National Antimicrobial Resistance Action Plan spanning from 2018 to 2023. This action plan outlines a comprehensive strategy to tackle AMR across multiple sectors and stakeholders, including the health sector, agriculture, animal husbandry, and environmental management. The implementation of this plan aims to curb the misuse and overuse of antibiotics, enhance surveillance and monitoring of resistant pathogens,

63 improve infection prevention and control practices, and promote responsible antimicrobial use in

64 both humans and animals. Even though the Uganda AMR national action plan, supports the

analysis, dissemination, and sharing of surveillance data and Information on AMR to facilitate,

66 decision-making on diagnoses and treatments in clinical public health, veterinary practice,

67 environment, and wildlife laboratories and food technologies, no data on molecular mechanisms

68 associated with resistance to Carbapenems in *Campylobacter* has been generated.

69 Campylobacter infections are a major cause of bacterial gastroenteritis worldwide [5], with

70 Campylobacter jejuni and Campylobacter coli being the primary species responsible for human

71 disease. The Centers for Disease Control and Prevention (CDC) estimated that a substantial

number of infections, approximately 300,000 cases per year in the United States alone, are caused

73 by drug-resistant *Campylobacter* strains [6]. This alarming trend underscores the urgent need for

74 comprehensive surveillance and understanding of AMR mechanisms in Campylobacter especially

in low-income settings such as Uganda.

Poultry, including chickens, plays a critical role in the epidemiology of AMR, especially in the context of *Campylobacter* species [7]. The transmission of resistant *Campylobacter* from poultry to humans is of significant concern, as it may compromise the effectiveness of commonly used antibiotics for the treatment of these infections. The proximity of humans to poultry and the potential for direct or indirect contact with contaminated poultry products contribute to the spread of AMR at the animals-humans-environment interface [8], amplifying the global burden of antimicrobial resistance.

83 The emergence and dissemination of carbapenem resistance in Gram-negative bacteria including

Campylobacter pose an alarming threat, as carbapenems are often considered as last-line treatment
options for severe bacterial infections [9].

Resistance to Carbapenems is commonly due to the production of Carbapenemases such as;
veronica integron metallo-beta-lactamase types (VIM), imipenemase (IMP) types, *Klebsiella pneumoniae* Carbapenemase (KPC), oxacillinase_48 (OXA_48), and New Delhi metallo-betalactamase-1 (NDM-1), encoded by Carbapenem resistance determining genes (CRDGs):*blaVIM*, *blaIMP*, *blaKPC*, *blaOXA_48*, and *blaNDM-1*, respectively [10]. Resistance to Carbapenems may
also be due to plasmid AmpC beta-lactamases in combination with ESBLs, mutations, and altered
expression of porins. The presence of carbapenem resistance genes in *Campylobacter* strains raises

93 concerns about the potential dissemination of these resistance determinants in the environment,

94 which could further contribute to the global spread of AMR.

Therefore, this research aimed to investigate the phenotypic resistance patterns to selected carbapenems and the prevalence of CRDGs in *C. coli* and *C. jejuni* isolated from chickens and diarrheic children aged less than five years in Kampala city, Uganda. This research will provide critical insights into the dynamics of carbapenem resistance in this pathogen and contribute to informing effective strategies for its control and prevention, ultimately protecting public health.

100

101 Materials And Methods

102 Study design

This was a cross-sectional study that aimed at determining phenotypic resistance patterns against
Meropenem and Imipenem and detecting four Carbapenem resistance genes (*blaOXA-48*, *blaNDM-1*, *blaVIM and blaIMP*) in archived samples of *Campylobacter species*, *C. coli, and C. jejuni* isolates at Food Hygiene Laboratory, Makerere University, College of Veterinary Medicine,
Animal Resources and Biosecurity (COVAB).

108 Study population

109 The study was conducted on all 292(48 from children and 244 from chickens) isolates of 110 Campylobacter species previously stored at -40°C in the Food Hygiene Laboratory at the 111 Department of Biosecurity, Ecosystems and Veterinary Public Health in 2021. The bacterial 112 isolates had been recovered from feacal and rectal swab samples from diarrheic children aged five 113 vears and below who were attending Mulago National Referral Hospital and Kisenvi Health Centre 114 III and from cloacal swabs of chickens in the childrens' homes or neighborhoods in Kampala city, 115 Uganda, between 2020 and 2021. These isolates were obtained using the method as described by 116 [11]. Briefly, faecal samples were cultured on Exeter broth and transferred to Modified Charcoal 117 Cefoperazone Deoxycholate Agar (MCCDA) through 0.45µm Nitrocellulose filters. Suspected 118 *Campylobacter* colonies were sub-cultured on blood agar and Identification was based on colony 119 morphology.

120

121 Retrieval of *Campylobacter* species isolates from storage.

122 The isolates and associated data were first accessed on 1st September 2022. Retrieval of isolates

123 and analysis of phenotypic antibiotic susceptibility patterns were performed from the Food Hygiene Laboratory at COVAB using the method by [11]. All the 292 cryopreserved samples of 124 125 Campylobacter species in Microbank (Oxoid) with 15% glycerol were resuscitated in nutrient 126 broth by pipetting 100µl of the glycerol stock in which the isolates were archived into 1ml of 127 nutrient broth. Incubation was done at 42°C for 24 hours under microaerophilic conditions created 128 by Campygen[®] (Oxoid, UK) gas-generating pack in an anaerobic jar. After 24-hour incubation, 129 100µl of the broth culture was transferred onto a 0.45micrometer nitrocellulose membrane filter 130 placed on sterile MCCDA (Blood-Free agar) (Oxoid, UK) containing *Campylobacter* selective 131 supplement SR0155 (Oxoid, UK). The fluid was spread on the filter using a sterile micro loop and allowed to drain through for 30 minutes. Incubation was then done for 24 hours at 42°C under 132 133 microaerophilic conditions created by Campygen[®] (Oxoid, UK) in an anaerobic jar. A pool of colonies from the MCCDA was emulsified in nutrient broth (Oxoid, UK) and transferred to the 134 135 Molecular Laboratory at COVAB for DNA extraction and identification of Campylobacter species using PCR. 136

137 Determination of phenotypic antimicrobial susceptibility patterns against Meropenem and 138 Imipenem in *Campylobacter* species isolates

139 All the archived isolates once resuscitated were subjected to antimicrobial susceptibility testing 140 using the Kirby-Bauer disk diffusion susceptibility testing Method [12]. The standardised bacterial 141 inoculum using 0.5 Mcfarland standards was grown on Mueller-Hinton agar (Oxoid, UK) in the presence of two Carbapenem antibiotics (Imipenem 10ug, Meropenem 10ug) (Oxoid, UK) and 142 incubated for 24 hours at an ambient temperature of 42°C in a microaerophilic condition provided 143 144 by Campygen[®]. At the end of incubation, the zone inhibition diameters were measured using a 145 ruler and a pair of dividers. The results of the zone inhibition diameters were interpreted as 146 resistant, intermediate, and susceptible following the Clinical and Laboratory Standards Institute 147 (CLSI), 2021 guidelines [13]. Details of the Carbapenem breakpoints are summarized in Table 1.

148 Table 1: Standard zone diameters for Imipenem and Meropenem CLSI, 2021 [13]

		ZONE DIAMETERS	
	Resistant	Intermediate	Susceptible
Imipenem and	<19 mm	20- 22 mm	\geq 23 mm
Meropenem			

149

Molecular identification of *Campylobacter* species and detection of carbapenem resistance genes

152 Campylobacter DNA Extraction

153 Wizard genomic DNA purification kit from PROMEGA (USA) was used to extract DNA based on the manufacturer's instructions: Centrifugation of 1ml of the overnight culture was done for 154 155 two minutes at 13,000 rpm and the supernatant was discarded. Nuclei Lysis Solution (600µl) was 156 added to the pellet and incubated for five minutes at 80°C, then cooled to room temperature. Three 157 microliters of RNase solution were added and incubated at 37°C for 60 minutes, then cooled to room temperature (25°C). Two hundred microliters of Protein precipitation solution were added, 158 159 vortexed, incubated on ice for five minutes, and centrifuged at 13,000 rpm for three minutes. The 160 supernatant was transferred to a clean tube containing 600µl of room-temperature isopropanol, 161 centrifuged, and the supernatant decanted. Seventy percent ethanol (600µl) was added to the pellet, 162 mixed, and centrifuged for two minutes at 13,000 rpm. The ethanol was aspirated, and the pellet 163 was air-dried for 10 minutes at 25°C. Finally, the DNA pellet was rehydrated in 100µl of 164 Rehydration Solution for one hour at 65°C.

165

166 Identification of genus Campylobacter, species C. coli and C. jejuni by PCR

Using a multiplex PCR, *Campylobacter species* 16S RNA gene, specific genes for *C. coli and C. jejuni (ask* and *cj0414* respectively) were amplified as described by [14]. Briefly, 1x of wifi Taq mix, 0.25µM of each forward and reverse primers (Table 2), and 1.5µl of the template DNA were mixed and topped up with PCR water to a 25µl reaction volume. The amplification was carried out in a thermocycler (Bio Rad, USA) using the following conditions: initial denaturation at 95°C for 15 minutes followed by 25 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 1 minute, extension at 72°C for 1 minute and a final extension at 72°C for 7 minutes.

174

175 Table 2: Primers used in the amplification of *Campylobacter* species, *C. coli* and *C. jejuni*

Target organism	Size (bp)	Tm	Target gene	Primer	Primer sequence	Reference
Genus <i>Campylobacter</i>	816		16S rRNA	C412F	GGATGACACTTTTC GGAGC	[15]
				C128R	CATTGTAGCACGTG TGTC	
C. coli,	502		Ask	CC18F	GGTATGATTTCTAC AAAGCGAG	[15]
				CC519R	ATAAAAGACTATCG TCGCGTG	
C. jejuni,	161		cj0414	C-1	CAAATAAAGTTAGA GGTAGAATGT	[16]
				C-3	CCATAAGCACTAGC TAGCTGAT	

176

The PCR amplicons were run on 2% agarose gel. The gel was run in Tris-acetate EDTA (TAE)
buffer at 125 voltage for 35 minutes in the presence of gel red for staining the DNA. The gel was
then visualised under a ultra-violet gel illuminator.

180

181 Multiplex PCR detection of Carbapenem resistance genes

Only positive samples for *Campylobacter species* 16S *RNA*, *C*, *coli*, and *C. jejuni* were subjected to the detection of resistance genes. My Taq Mix (Bioline, Alvinston, Canada) of 2x Concentration was used to perform the Multiplex PCR to detect the four resistance genes (blaOXA_48, blaNDM-*I*, *blaIMP*, and blaVIM) using eight primers shown in table 3. These four genes were selected because of their clinical significance and being the most commonly reported carbapenem resistance genes in other bacteria such as the *Enterobacteriaceae*.

188 A total PCR reaction of 12.5 μ l was used comprising 6.25 μ l of 2x My Taq Mix, 0.25 μ l of 10 μ M

189 of both Forward and reverse primer, and 2µl of DNA template and nuclease-free water was used

190 to top up to 12.5 µl total reaction mix. The following PCR programs were used, initial

denaturation at 94°C for 5 minutes, followed by 40 cycles of denaturation at 94°C for 45 seconds,

annealing at 50°C for 1 minute, extension at 72° C for 1 minute, one final cycle of extension at

- 193 72° C for 10 minutes and hold at 4° C for infinity. Electrophoresis was done to detect the presence
- 194 of the resistance genes and run on 2% agarose gel at 100V, 300MA for 50 minutes, and DNA
- stained with 3x Gel Red. The gel was then visualised under a UV gel illuminator.
- 196

197 Table 3: Primers for amplification of four selected Carbapenem resistance genes

Gene	Primer sequence (5-3)	Amplicons size(bp)	Reference	
	Forward:			
blaNDM-1	GGIIIGGCGAICIGGIIIIC		[10]	
	Reverse: CGGAATGGCTCATCACGATC	521	L J	
	Forward:			
h1 IVINA	GATGGTGTTTGGTCGCATA		[10]	
DIAV IM	Reverse:	200		
	CGAATGCGCAGCACCAG	390		
	Forward:			
blaOXA-	GCTTGATCGCCCTCGATT		[10]	
48	Reverse:	220		
	GATTTGCTCCGTGGCCGAAA	238		
	Forward:	507	[17]	
Diaiwir	GAAGGCGTTTATGTTCATAC	307	[1/]	
	Reverse:			
	GTAAGTTTCAAGAGTGATGC			

198

199

200 Data analysis

201 The phenotypic antibiotic susceptibility patterns and Carbapenem resistance genes for each isolate 202 were recorded as per sample identification numbers. All results obtained were verified for any 203 clerical errors by comparing the final lab report results with the raw data generated in the lab that 204 detailed every step undertaken before concluding on the results reported. After the verification 205 process, the generated data were coded and entered in Microsoft Excel and then exported to 206 STATA 14 software for analysis. Data analysis was conducted in STATA version 14, proportion differences were computed using the Chi-square test, and statistical differences were determined 207 208 at 0.05 level of significance and 95% confidence level.

209 Ethical considerations

210 This study did not require ethical approval as it focused on archived isolates. However, permission 211 to use the isolates was sought from the Principal Investigator of the primary study that obtained 212 the isolates. The primary study underwent review and approval by the School of Health Sciences, 213 Makerere University Research Ethical Committee and received approval from the School of 214 Health Sciences Research Ethics Committee (SHSREC REF. 2020/034), also uploaded as 'others'. The approved informed consent included the option to utilize stored isolates for further research 215 216 purposes. Written consent was obtained from care takers of the children whose stool samples were 217 collected in the primary study. All files containing electronic data were password-protected. 218 Laboratory identification numbers previously used for sample isolation, which concealed patients' 219 identities, were retained during this analysis.

220

221 Results

222

Phenotypic antimicrobial resistance patterns of *Campylobacter species* against Meropenem and Imipenem

All 292(100%) isolates of *C. coli* and *C. jejuni* were phenotypically susceptible to both Meropenem and Imipenem antibiotics, (Zone of inhibition diameters ranged from 33-48mm, Mean and SD= 41.5 4.2 respectively)

228

229 Molecular identification of Campylobacter species, C. coli and C. jejuni

230

Out of the 292 isolates of Campylobacter species included in this study, 288(98.6%) of the isolates 231 232 were positive for genus Campylobacter 16S RNA gene, of which 31(10.8%) were C. jejuni, 233 204(70.8%) were C. coli, 50(17.4%) mixed isolates of C. coli and C. jejuni and 3(1.0%) were 234 genus Campylobacter but neither C. coli nor C. jejuni. Of the 235 isolates confirmed as C. coli 235 and C. jejuni, 39(16.60%) were from children aged less than five years and 196(83.40%) were 236 from chicken. 38(97.44%) of the 39 isolates from children were C. coli, 1(2.56%) was C. jejuni; 237 and 166(84.69%) of the 196 isolates from chicken were C. coli and 30 (15.31%) were C. jejuni. A 238 representative agarose gel for multiplex PCR amplification of Campylobacter species 16S RNA 239 genes, C. coli, and C. jejuni specific genes is shown in figure 1.

240

241 Fig 1: Representative agarose gel for multiplex PCR amplification of Campylobacter species 16S

242 RNA genes, C. coli, and C. jejuni specific genes

- 243 Lane M: Molecular marker-50bp (Bioline, Alvinston, Canada). Lane NC: Negative control
- 244 (Distiled water). Lane PC: Positive control- C. coli (ATCC 33559, Thermo Fisher, US) positive
- control. Lanes 1-14 test samples. Lane 2 is Campylobacter species different from C. coli and C.
- 246 *jejuni; Samples 1-14 are all positive for Campylobacter species 16S RNA gene, and sample 2 is a*
- 247 Campylobacter species different from C. coli and C. jejuni. Lanes 3, 6, 10, and 13 have both C.
- coli and C. jejuni. Campylobacter species were detected on a gel by the presence of 816bp band,
- 249 while C. coli and C. jejuni had bands of 502bp and 161bp, respectively.
- 250

251 Prevalence of Carbapenem resistance genes in *C. coli* and *C. jejuni*.

252

Out of the 235 isolates of *C. coli* and *C. jejuni*, 70(29.8%, 95% Conf. Interval= 0.2424904 0.3598934) were positive for at least one of the four carbapenem resistance genes targeted in this study with a higher prevalence in *C. jejuni*, 16(51.6%) than in *C. coli*, 54(26.5%). The prevalence of the resistance genes was 55(78.5%, CI= 0.6712809-0.8681365) in chickens and 15(21.4%, CI= 0.1318635-0.3287191) in children.

Overall, the most predominant gene was blaVIM 40(57.1%), followed by blaNDM-1 8(11.4%), blaIMP 6(8.6%) and blaOXA-48 was 4(5.7%). A combination of blaVIM and blaIMP was 7(10.0%), blaVIM and blaNDM-1 4(5.7%), and 1(1.4%) had blaNDM-1, blaVIM and blaIMP. The difference in the prevalence of the genes in *C. coli* and *C.jejuni* was statically significant (Chisquare value= 4.0358 and P-value = 0.045) as shown in table 4 and 5. A representative agarose gel for multiplex PCR amplification of selected carbapenem resistance genes (blaVIM, blaIDM-1, blaOXA-48, and blaIMP) in *C. coli* and *C. jejuni* is shown in figure 2.

- 265
- 266
- 267

Fig 2: Representative agarose gel for multiplex PCR amplification of selected carbapenem resistance genes (blaVIM, blaIDM-1, blaOXA-48, and blaIMP) in *C. coli* and *C. jejuni*

- 270 Lane LM: Molecular marker-50bp (Bioline, Alvinston, Canada). Lanes S1-S10 tested samples.
- 271 Samples S2, S3, S5 and S8 were positive for blaOXA-48; samples S1, S2, and S6 were positive for

- 272 blaVIM; samples S2, S3 and S8 were positive for blaNDM-1; Samples S1, and S6 were positive
- 273 for blaIMP. Carbapenem resistance genes; blaNDM-1, blaVIM, blaOXA-48, and blaIMP were
- detected on a gel by the presence of band sizes of 521bp, 390bp, 238bp, and 587bp, respectively.
- 275 Table 4: Frequency of Carbapenem resistance genes in C. coli and C. jejuni isolates
- 276
- 277

Source of isolates	Test organism	Carbapenem resistance genes			
		Negative n (%)	Positive n (%)	subtotal-N (%)	
Chicken	C. coli	127(76.5)	39(23.5)	166(84.7)	
	C. jejuni	14(6.7)	16(53.3)	30(15.3)	
subtotal		141(70.9)	55(28.1)	196(83.4)	
Children	C. coli	23(60.5)	15(39.5)	38(97.4)	
	C. jejuni	1(100.0)	0(0.0)	1(2.6)	
subtotal		24(61.5)	15(38.5)	39(16.7)	
Total-N (%)		165(70.2)	70(29.8)	235(100)	

278

279

280 Table 5: Frequency of four selected carbapenem resistance genes in *C. coli* and *C. jejuni*

	Species			
Carbapenem resistance gene	C. coli-n (%)	C. jejuni-n (%)	Total-N (%)	
blaIMP	5(7.1)	1(1.4)	6(8.6)	
blaNDM-1	6(8.6)	2(2.9)	8(11.4)	
blaVIM	32(45.7)	8(11.4)	40(57.1)	
blaOXA-48	2(2.9)	2(2.9)	4(5.7)	
blaVIM and blaNDM	2(2.9)	2(2.9)	4(5.7)	
blaNDM, blaVIM and	1(1.4)	0(0.0)	1(1.4)	

blaIMP				
blaVIM	and	6(8.6)	1(1.4)	7(10.0)
blaIMP				
Total		54	16	70
		77.1%	22.9%	100.0%

281

282

283 Discussion

11 0 0

284 Carbapenem resistance is a growing concern in bacterial infections, as these drugs are considered 285 last-resort antibiotics. This study focused on detecting carbapenem resistance genes in 286 *Campylobacter coli* and *Campylobacter jejuni* isolates from children and chicken. Interestingly, 287 all the isolates obtained from diarrheic children and chickens were found to be phenotypically 288 susceptible to Meropenem and Imipenem, which is consistent with the fact that carbapenems are 289 not currently used to treat Campylobacter infections in humans and are not licensed for use in 290 animal medicine [18]. This is similar to a study conducted by [19] which reported no resistance to 291 Meropenem and Imipenem in *Campylobacter species* isolated from international travelers. 292 However, it is important to note that with time and increased use of carbapenems, even in animal 293 medicine, resistance is likely to emerge. Although the Campylobacter species in this study did not 294 exhibit phenotypic resistance to Meropenem and Imipenem, other pathogens in Uganda have 295 shown resistance to these antibiotics. For example [20] reported prevalence of 33% and 21% in 296 P. aeruginosa from patients and the environment respectively while it was 14% and 86% in A. 297 baumannii from patients and environment respectively at Mulago hospital. Moreover, [21] 298 reported 22.4% in *Enterobacteriaceae* at Mulago hospital, Kampala. These findings highlight the 299 importance of monitoring resistance patterns in different bacterial species and environments.

The prevalence of carbapenem resistance genes in the *Campylobacter* isolates in this study was 29.79%, which is consistent with previous studies on carbapenem resistance genes in other bacteria in Uganda. For instance, a study on *Enterobacteriaceae* at Mulago Hospital reported a prevalence of 28.6%, while *Acinetobacter baumannii* and *Pseudomonas aeruginosa* showed prevalence rates of 2.7% and 7.4%, respectively [21]. Similar to Enterobacteriaceae, *Campylobacter* species possess mobile genetic elements that can facilitate the horizontal transfer of resistance genes [22].

This emphasizes the need for further research on the mechanisms of gene transfer and integron dynamics to understand the spread and persistence of carbapenem resistance genes in *Campylobacter* in the environment.

309 The results also revealed that 28.1% (55 out of 196) of Campylobacter isolates from chickens were 310 positive for carbapenem resistance genes, while 38.5% (15 out of 39) of *Campylobacter* isolates 311 from children carried these resistance genes. This prevalence indicates a concerning level of 312 carbapenem resistance genes in both chicken and children's populations in Kampala city, Uganda. 313 The high prevalence of carbapenem resistance genes in *Campylobacter* isolates from chickens is 314 consistent with previous studies that have identified poultry as a significant reservoir for antimicrobial-resistant bacteria [23]. The poultry industry often employs the widespread use of 315 316 antibiotics, including critically important carbapenems-like antimicrobials such as cephalosporins, to promote growth and prevent diseases in chickens [24]. Such practices create a favorable 317 318 environment for the selection and persistence of resistant bacteria in chicken populations.

The higher prevalence of carbapenem resistance genes in Campylobacter isolates from children is particularly concerning. It raises the possibility of release into the environment and transmission of drug resistant *Campylobacter* from human sources to poultry and vice versa possibly through the consumption of contaminated feeds/food and contact with infected chickens. Children, especially those in low-resource settings, are particularly vulnerable to the infection [25], and the presence of carbapenem-resistant *Campylobacter* in this population raises significant public health concerns.

326

327 Among the carbapenem resistance genes detected, blaVIM was the most prevalent at 57.1%, which 328 aligns with a previous study that reported blaVIM as the most common gene at 10.1%[21]. 329 Interestingly, all the detected genes (blaVIM, blaNDM-1, blaIMP, and blaOXA-48) were present 330 in C. coli and C. jejuni isolates, despite these isolates being phenotypically susceptible to 331 Meropenem and Imipenem. This suggests that the development of resistance due to the presence 332 of carbapenems in the environment was unlikely as previous studies have indicated that resistance 333 genes can be expressed in the presence of antibiotics in the environment [26]. The high prevalence 334 of blaVIM in this study is suggestive of the role of the accessory genome in evolution of 335 carbapenem resistance in the environment. The blaVIM is characterized as an acquired MBL gene 336 translocated between bacteria via class-1 integrons, in horizontal gene transfer mechanisms mostly

337 involving conjugative plasmids [27] & [22]. This makes it essential to conduct further research on 338 the mechanisms of horizontal gene transfer and integron dynamics. Understanding the molecular 339 pathways of gene transfer will provide insights into the spread and persistence of carbapenem 340 resistance genes in the environment, enabling the development of targeted interventions and 341 control strategies. It is also important to conduct regular monitoring of environmental sources for the presence of carbapenem resistance genes. Regular monitoring of environmental sources, such 342 343 as wastewater, agricultural runoff, and other potential reservoirs, is also crucial to assess the extent of environmental contamination and identify possible transmission routes. 344

345 The study detected a low prevalence of blaOXA-48 at 2.9% among the isolates. This can be attributed to the unique characteristics of OXA-48-like enzymes, which have low or no hydrolytic 346 347 activity towards carbapenems [28]. Additionally, the identification of OXA-48-type producers can be challenging due to their point mutant analogs with extended-spectrum beta-lactamases (ESBLs) 348 349 [29]. Hence, estimating the true prevalence rates of OXA-48-like producers is difficult. This study 350 also found co-existence of blaVIM, blaNDM, and blaIMP in C. coli and C. jejuni isolates at 351 9(12.9%), indicating that the isolates have the potential for resistance to multiple carbapenem 352 drugs. Although carbapenems have never been licensed for use in livestock animals in any country 353 [30], sporadic cases of carbapenemase-producing bacteria have not only been reported in companion animals but also in livestock, food, and wild animals [31]. Therefore, besides 354 355 nosocomial bacteria, the food chain and other reservoirs may contribute to the transmission of 356 carbapenem resistance [32]. Strict regulations and discouraging the use of carbapenems in animals 357 are crucial to prevent the emergence and spread of carbapenem resistance genes at the livestock-358 human interface.

359

360 Conclusions

This study revealed that all the isolates were susceptible to Meropenem and Imipenem. This study also has, for the first time, reported a high prevalence of carbapenem resistance genes in *C. coli* and *C. jejuni* globally at 29.8%. The blaVIM was the most prevalent carbapenem resistance gene.

365 Limitation of the study

366 Samples were collected from limited geographic space, mainly hospital based, and the number was367 quite small. This impacted the generalizability of the results.

368

369 **Recommendations**

370

Further research and analysis to identify and characterize *Campylobacter* species other than *C. coli* and *C. jejuni* should be conducted in such settings as in this study. This investigation should focus on understanding their genetic diversity, resistance gene profiles, and potential involvement in carbapenem resistance. A better understanding of these species will aid in developing targeted interventions and control strategies.

A comprehensive assessment of the current utilization and management practices of carbapenems in both human and animal settings in Uganda should be conducted. This assessment should include surveys, interviews, and data collection from healthcare facilities, veterinary clinics, and farms to determine the extent of carbapenem usage, prescribing patterns, and adherence to guidelines. This information will help identify potential sources of carbapenem resistance and inform future intervention strategies.

A comprehensive surveillance system to monitor the prevalence and trends of carbapenem resistance specifically in *Campylobacter* isolates from diarrheic children and chickens should be established. This surveillance should involve routine testing of isolates for carbapenem resistance genes and phenotypic susceptibility. Timely data collection and analysis will facilitate early detection of emerging resistance patterns and inform targeted interventions.

387 A robust antibiotic stewardship programs in healthcare and veterinary settings in Uganda should 388 be developed and implemented. These programs should focus on promoting responsible use of 389 carbapenems, ensuring appropriate prescribing practices, and monitoring antimicrobial 390 consumption. Collaboration between human and animal health sectors is crucial to address the 391 potential overlap in antibiotic usage and to harmonize stewardship efforts.

392

393 Authors' contributions

WO, AN, and TO: conceptualization. WO, TO, AN, JO and FLO: data collection. WO, JO, AN,

and TO: formal analysis. OW, TO, and AN: investigations. WO, AN, CK and TO: methodology.

396 WO, AN, TO: discussion. WO, CK, AN, PM, LN, DO, JO, and FLO: writing original draft. WO,

- 397 JO, AN, LN, and TO: writing final draft. PP, CK, and TO: resources. CK, AN, TO, and PP:
- 398 supervision. All authors contributed to the article and approved the submitted version.

399						
400	Fund	ing				
401	This s	This study was funded by Norwegian Agency for Development Cooperation (NORAD) through				
402	the N	he Norwegian Programme for Capacity Development in Higher Education and Research for				
403	Devel	opment (NORHED II) project titled "Climate Change and infectious Diseases Management,				
404	a One	e Health Approach" and Department of Population Health Sciences, Virginia-Maryland				
405	Colleg	ge of Veterinary Medicine.				
406	Ackn	owledgment				
407	Our si	incere appreciation to the Norway government through NORHED II and the Department of				
408	Popul	ation Health Sciences, Virginia-Maryland College of Veterinary Medicine for funding this				
409	resear	rch. A special appreciation also to the staff of Molecular Biology and Food Hygiene				
410	Labor	atories of COVAB, Makerere University for the technical assistance during the laboratory				
411	phase of this study.					
412						
413	Refer	ences				
414						
415	[1]	F. Prestinaci, P. Pezzotti, and A. Pantosti, "Antimicrobial resistance: a global multifaceted				
416		phenomenon," Pathog. Glob. Health, vol. 109, no. 7, pp. 309-318, 2015.				
417	[2]	W. H. Organization, Antimicrobial resistance: global report on surveillance. World				
418		Health Organization, 2014.				
419	[3]	D. van Duin and Y. Doi, "The global epidemiology of carbapenemase-producing				
420		Enterobacteriaceae," Virulence, vol. 8, no. 4, pp. 460-469, 2017.				
421	[4]	M. Kimaanga, "Temporal dynamics of enterobacteriaceae antimicrobial resistance at the				
422		human-pig interface in peri-urban Kampala." Makerere University, 2019.				
423	[5]	N. O. Kaakoush, N. Castaño-Rodríguez, H. M. Mitchell, and S. M. Man, "Global				
424		epidemiology of Campylobacter infection," Clin. Microbiol. Rev., vol. 28, no. 3, pp. 687-				
425		720, 2015.				
426	[6]	C. A. Whitehouse, S. Zhao, and H. Tate, "Antimicrobial resistance in Campylobacter				
427		species: mechanisms and genomic epidemiology," Adv. Appl. Microbiol., vol. 103, pp. 1-				
428		47, 2018.				
429	[7]	J. Kim et al., "Comparative analysis of aerotolerance, antibiotic resistance, and virulence				

- 430 gene prevalence in Campylobacter jejuni isolates from retail raw chicken and duck meat
 431 in South Korea," *Microorganisms*, vol. 7, no. 10, p. 433, 2019.
- 432 [8] S. A. Khan, M. A. Imtiaz, M. A. Sayeed, A. H. Shaikat, and M. M. Hassan,
- 433 "Antimicrobial resistance pattern in domestic animal-wildlife-environmental niche via the
- food chain to humans with a Bangladesh perspective; a systematic review," *BMC Vet.*
- 435 *Res.*, vol. 16, pp. 1–13, 2020.
- 436 [9] H. J. Morrill, J. M. Pogue, K. S. Kaye, and K. L. LaPlante, "Treatment options for
 437 carbapenem-resistant Enterobacteriaceae infections," in *Open forum infectious diseases*,
 438 2015, vol. 2, no. 2.
- 439 [10] M. F. Mushi, S. E. Mshana, C. Imirzalioglu, and F. Bwanga, "Carbapenemase genes 440 among multidrug resistant gram negative clinical isolates from a tertiary hospital in 441 Mwanza, Tanzania," *Biomed Res. Int.*, vol. 2014, 2014.
- L. K. Williams, L. C. Sait, T. A. Cogan, F. Jørgensen, R. Grogono-Thomas, and T. J.
 Humphrey, "Enrichment culture can bias the isolation of Campylobacter subtypes," *Epidemiol. Infect.*, vol. 140, no. 7, pp. 1227–1235, 2012.
- 445 [12] J. Hudzicki, "Kirby-Bauer disk diffusion susceptibility test protocol," *Am. Soc.*446 *Microbiol.*, vol. 15, pp. 55–63, 2009.
- 447 [13] I. I. Lewis and S. James, "Performance standards for antimicrobial susceptibility testing,"
 448 (*No Title*), 2022.
- 449 [14] B. da S. Frasao, V. A. Marin, and C. A. Conte-Junior, "Molecular detection, typing, and
 450 quantification of Campylobacter spp. in foods of animal origin," *Compr. Rev. Food Sci.*451 *Food Saf.*, vol. 16, no. 4, pp. 721–734, 2017.
- 452 [15] D. Linton, A. J. Lawson, R. J. Owen, and J. Stanley, "PCR detection, identification to
 453 species level, and fingerprinting of Campylobacter jejuni and Campylobacter coli direct
 454 from diarrheic samples," *J. Clin. Microbiol.*, vol. 35, no. 10, pp. 2568–2572, 1997.
- 455 [16] R. WANG, M. F. SLAVIK, and W. CAO, "A RAPID PCR METHOD FOR DIRECT
- 456 DETECTION of LOW NUMBERS of CAMPYLOBACTER JEJUNI 1," *J. Rapid*457 *Methods Autom. Microbiol.*, vol. 1, no. 2, pp. 101–108, 1992.
- 458 [17] S. A. Khalaf, N. N. Mahmood, and M. A. D. Saleh, "Detection of tetM, armA, blaPER-1
 459 and blaIMP genes in E. coli isolates among the gram negative bacteria that cause urinary
 460 tract infections," in *Journal of Physics: Conference Series*, 2021, vol. 1999, no. 1, p.

⁴⁶¹ 12021. M. Bassetti, M. Peghin, and D. Pecori, "The management of multidrug-resistant 462 [18] 463 Enterobacteriaceae," Curr. Opin. Infect. Dis., vol. 29, no. 6, pp. 583-594, 2016. 464 [19] A. Post et al., "Antibiotic susceptibility profiles among Campylobacter isolates obtained 465 from international travelers between 2007 and 2014," Eur. J. Clin. Microbiol. Infect. Dis., vol. 36, no. 11, pp. 2101-2107, 2017. 466 467 [20] D. P. Kateete, R. Nakanjako, M. Okee, M. L. Joloba, and C. F. Najjuka, "Genotypic 468 diversity among multidrug resistant Pseudomonas aeruginosa and Acinetobacter species at 469 Mulago Hospital in Kampala, Uganda," BMC Res. Notes, vol. 10, no. 1, pp. 1-10, 2017. D. Okoche, B. B. Asiimwe, F. A. Katabazi, L. Kato, and C. F. Najjuka, "Prevalence and 470 [21] 471 characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago 472 National Referral Hospital, Uganda," PLoS One, vol. 10, no. 8, p. e0135745, 2015. V. L. Kung, E. A. Ozer, and A. R. Hauser, "The accessory genome of Pseudomonas 473 [22] aeruginosa," Microbiol. Mol. Biol. Rev., vol. 74, no. 4, pp. 621-641, 2010. 474 [23] C. M. Schroeder, D. G. White, and J. Meng, "Retail meat and poultry as a reservoir of 475 antimicrobial-resistant Escherichia coli," Food Microbiol., vol. 21, no. 3, pp. 249-255, 476 477 2004. C. H. Brower et al., "The prevalence of extended-spectrum beta-lactamase-producing 478 [24] 479 multidrug-resistant Escherichia coli in poultry chickens and variation according to farming 480 practices in Punjab, India," Environ. Health Perspect., vol. 125, no. 7, p. 77015, 2017. S. Budge et al., "Risk factors and transmission pathways associated with infant 481 [25] 482 Campylobacter spp. prevalence and malnutrition: A formative study in rural Ethiopia," 483 PLoS One, vol. 15, no. 5, p. e0232541, 2020. 484 [26] H. Knothe, P. Shah, V. Krcmery, M. Antal, and S. Mitsuhashi, "Transferable resistance to 485 cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella 486 pneumoniae and Serratia marcescens," Infection, vol. 11, no. 6, pp. 315–317, 1983. G. J. Da Silva and S. Domingues, "Insights on the horizontal gene transfer of 487 [27] 488 carbapenemase determinants in the opportunistic pathogen Acinetobacter baumannii," 489 Microorganisms, vol. 4, no. 3, p. 29, 2016. 490 M. Rivera-Izquierdo et al., "OXA-48 carbapenemase-producing enterobacterales in [28] 491 Spanish hospitals: An updated comprehensive review on a rising antimicrobial

492		resistance," Antibiotics, vol. 10, no. 1, p. 89, 2021.
493	[29]	F. S. Codjoe and E. S. Donkor, "Carbapenem resistance: a review," Med. Sci., vol. 6, no.
494		1, p. 1, 2017.
495	[30]	J. Fernández, B. Guerra, and M. R. Rodicio, "Resistance to carbapenems in non-typhoidal
496		Salmonella enterica serovars from humans, animals and food," Vet. Sci., vol. 5, no. 2, p.
497		40, 2018.
498	[31]	N. Woodford, D. W. Wareham, B. Guerra, and C. Teale, "Carbapenemase-producing
499		Enterobacteriaceae and non-Enterobacteriaceae from animals and the environment: an
500		emerging public health risk of our own making?," J. Antimicrob. Chemother., vol. 69, no.
501		2, pp. 287–291, 2014.
502	[32]	I. Kühn et al., "Epidemiology and ecology of enterococci, with special reference to
503		antibiotic resistant strains, in animals, humans and the environment: example of an
504		ongoing project within the European research programme," Int. J. Antimicrob. Agents,
505		vol. 14, no. 4, pp. 337–342, 2000.
506		



